CoChat
Sign Up
Cited by 94Sarcoidosis and Beryllium Toxicity ResearchHistiocytic Disorders and TreatmentsCardiac tumors and thrombi

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review

Open access
Gilotra, NISHA A., GRIFFIN, JAN M., PAVLOVIC, NOELLE, HOUSTON, BRIAN A., CHASLER, JESSICA, GOETZ, COLLEEN, CHRISPIN, JONATHAN, SHARP, MICHELLE, KASPER, EDWARD K., CHEN, EDWARD S., BLANKSTEIN, RON, COOPER, LESLIE T., JOYCE, EMER, SHEIKH, FAROOQ H.·2022·Journal of Cardiac Failure
DOI 10.1016/j.cardfail.2021.06.016PMC PMC8748280
Open this paper in CoChat — free account

Abstract

The prevalence of sarcoidosis-related cardiomyopathy is increasing. Sarcoidosis impacts cardiac function through granulomatous infiltration of the heart, resulting in conduction disease, arrhythmia, and/or heart failure. The diagnosis of cardiac sarcoidosis (CS) can be challenging and requires clinician awareness as well as differentiation from overlapping diagnostic phenotypes, such as other forms of myocarditis and arrhythmogenic cardiomyopathy. Clinical manifestations, extracardiac involvement, histopathology, and advanced cardiac imaging can all lend support to a diagnosis of CS. The mainstay of therapy for CS is immunosuppression; however, no prospective clinical trials exist to guide management. Patients may progress to developing advanced heart failure or ventricular arrhythmia, for which ventricular assist device therapies or heart transplantation may be considered. The existing knowledge gaps in CS call for an interdisciplinary approach to both patient care and future investigation to improve mechanistic understanding and therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cardfail.2021.06.016

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In giant cell myocarditis and cardiac sarcoidosis, macrophages are a significant contributor to the formation of multinucleated giant cells or granulomas.

    “In well-known forms of autoimmune myocarditis such as giant cell myocarditis and cardiac sarcoidosis, macrophages have been identified as a significant contributor to the formation of multinucleated giant cells or granulomas”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [108]

    The Pathobiology of Sarcoidosis section says macrophages are the dominant constituent of sarcoidosis granulomas, and the Diagnosis of Cardiac Sarcoidosis section identifies granulomatous inflammation in cardiac tissue. The paper mentions giant cell myocarditis as a diagnosis to rule out, but does not say that macrophages form its multinucleated giant cells. It also does not explicitly describe macrophages forming sarcoid granulomas. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Sarcoidosis is a systemic autoimmune syndrome characterized by nonnecrotizing granulomas in various organs including the lung and heart.

    “Sarcoidosis is a systemic autoimmune syndrome characterized by the formation of nonnecrotizing granulomas, a histological hallmark, found in various organs including the lung and heart.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [108]

    The Introduction describes sarcoidosis as a systemic granulomatous inflammatory disease that most commonly affects the lungs and can involve the heart. The Pathobiology section describes non-necrotizing granulomatous inflammation, but calls sarcoidosis a systemic inflammatory disorder rather than an autoimmune syndrome; our copy does not establish that more specific classification. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 129

  1. Longcope, 1941, Sarcoidosis, or Besnier-Boeck-Schaumann disease: the Frank Billings Lecture, JAMA, 117, 1321, 10.1001/jama.1941.02820420013005 · DOI
  2. Baughman, 2003, Sarcoidosis, . Lancet, 361, 1111, 10.1016/S0140-6736(03)12888-7 · DOI
  3. Patel, 2009, Detection of myocardial damage in patients with sarcoidosis, Circulation, 120, 1969, 10.1161/CIRCULATIONAHA.109.851352 · DOI
  4. Kandolin, 2015, Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study, Circulation, 131, 624, 10.1161/CIRCULATIONAHA.114.011522 · DOI
  5. Yafasova, 2020, Long-term adverse cardiac outcomes in patients with sarcoidosis, J Am Coll Cardiol, 76, 767, 10.1016/j.jacc.2020.06.038 · DOI
  6. Moller, 2017, Genetic, immunologic, and environmental basis of sarcoidosis, Ann Am Thorac Soc, 14, S429, 10.1513/AnnalsATS.201707-565OT · DOI
  7. Su, 2013, Interferon-inducible chemokines reflect severity and progression in sarcoidosis, Respir Res, 14, 121, 10.1186/1465-9921-14-121 · DOI
  8. Ramstein, 2016, IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells, Am J Respir Crit Care Med, 193, 1281, 10.1164/rccm.201507-1499OC · DOI · Paper page
  9. Liu, 2016, The circulating Treg/Th17 cell ratio is correlated with relapse and treatment response in pulmonary sarcoidosis patients after corticosteroid withdrawal, PLoS One, 11
  10. Naruse, 2000, HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis, Tissue Antigens, 56, 52, 10.1034/j.1399-0039.2000.560107.x · DOI
  11. Grunewald, 2016, T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis, Eur Respir J, 47, 898, 10.1183/13993003.01209-2015 · DOI
  12. Chen, 2008, T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis, J Immunol, 181, 8784, 10.4049/jimmunol.181.12.8784 · DOI
  13. Ostadkarampour, 2014, Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren's syndrome, Clin Exp Immunol, 178, 342, 10.1111/cei.12403 · DOI
  14. Wiken, 2009, Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis, J Clin Immunol, 29, 78, 10.1007/s10875-008-9225-0 · DOI
  15. Chen, 2010, Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2, Am J Respir Crit Care Med, 181, 360, 10.1164/rccm.200905-0696OC · DOI
  16. Gabrilovich, 2013, Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis, Clin Exp Immunol, 173, 512, 10.1111/cei.12138 · DOI
  17. Stanton, 2003, Immunophenotyping of macrophages in human pulmonary tuberculosis and sarcoidosis, Int J Exp Pathol, 84, 289, 10.1111/j.0959-9673.2003.00365.x · DOI · Paper page
  18. Prokop, 2011, M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis, Am J Pathol, 178, 1279, 10.1016/j.ajpath.2010.11.065 · DOI
  19. Li, 2009, Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis, Circ Res, 105, 353, 10.1161/CIRCRESAHA.109.195230 · DOI
  20. Heymans, 2016, The quest for new approaches in myocarditis and inflammatory cardiomyopathy, J Am Coll Cardiol, 68, 2348, 10.1016/j.jacc.2016.09.937 · DOI · Paper page
  21. Cozier, 2011, Sarcoidosis in black women in the United States: data from the Black Women's Health Study, Chest, 139, 144, 10.1378/chest.10-0413 · DOI
  22. Rybicki, 2001, Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS), Am J Respir Crit Care Med, 164, 2085, 10.1164/ajrccm.164.11.2106001 · DOI
  23. Dumas, 2016, Epidemiology of sarcoidosis in a prospective cohort study of U.S. Women, . Ann Am Thorac Soc, 13, 67, 10.1513/AnnalsATS.201508-568BC · DOI
  24. Morimoto, 2008, Epidemiology of sarcoidosis in Japan, Eur Respir J, 31, 372, 10.1183/09031936.00075307 · DOI
  25. Martusewicz-Boros, 2016, Cardiac sarcoidosis: is it more common in men?, Lung, 194, 61, 10.1007/s00408-015-9805-8 · DOI
  26. Fussner, 2018, Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres, Eur J Heart Fail, 20, 1713, 10.1002/ejhf.1319 · DOI
  27. Ning, 2019, Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis, J Card Fail, 25, 307, 10.1016/j.cardfail.2019.02.018 · DOI
  28. Roberts, 1977, Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11), Am J Med, 63, 86, 10.1016/0002-9343(77)90121-8 · DOI · Paper page
  29. Birnie, 2016, Cardiac sarcoidosis, J Am Coll Cardiol, 68, 411, 10.1016/j.jacc.2016.03.605 · DOI · Paper page
  30. Hulten, 2016, Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis, Circ Cardiovasc Imaging, 9, 10.1161/CIRCIMAGING.116.005001 · DOI
  31. Birnie, 2014, HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, Heart Rhythm, 11, 1305, 10.1016/j.hrthm.2014.03.043 · DOI
  32. Ekstrom, 2019, Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries, Eur Heart J, 40, 3121, 10.1093/eurheartj/ehz428 · DOI
  33. Nery, 2014, Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia, Pacing Clin Electrophysiol, 37, 364, 10.1111/pace.12277 · DOI
  34. Roberts, 2009, Cardiac transplantation for cardiac sarcoidosis with initial diagnosis by examination of the left ventricular apical "core" excised for insertion of a left ventricular assist device for severe chronic heart failure, Am J Cardiol, 103, 110, 10.1016/j.amjcard.2008.08.053 · DOI
  35. Hiraga, 2007, Diagnostic standard and guidelines for sarcoidosis, Jpn J Sarcoidosis Granulomatous Disord, 27, 102
  36. Terasaki, 2017, New guidelines for diagnosis of cardiac sarcoidosis in Japan, Ann Nuclear Cardiol, 3, 42, 10.17996/anc.17-00042 · DOI
  37. Judson, 2014, The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool, Sarcoidosis Vasc Diffuse Lung Dis, 31, 19
  38. Ribeiro Neto, 2020, Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: is it time to regroup?, Am Heart J, 223, 106, 10.1016/j.ahj.2020.02.008 · DOI
  39. Ueberham, 2021, Current diagnostic criteria show a substantial disagreement in classification of patients with suspected cardiac sarcoidosis, JACC Clin Electrophysiol, 7, 538, 10.1016/j.jacep.2020.12.011 · DOI
  40. Trivieri, 2020, Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review, J Am Coll Cardiol, 76, 1878, 10.1016/j.jacc.2020.08.042 · DOI
  41. Rosenfeld, 2021, Arrhythmias in cardiac sarcoidosis bench to bedside: a case-based review, Circ Arrhythm Electrophysiol, 14, 10.1161/CIRCEP.120.009203 · DOI
  42. Burstow, 1989, Two-dimensional echocardiographic findings in systemic sarcoidosis, Am J Cardiol, 63, 478, 10.1016/0002-9149(89)90323-8 · DOI
  43. Hulten, 2016, Cardiac sarcoidosis-state of the art review, Cardiovasc Diagn Ther, 6, 50
  44. Agarwal, 2014, Cardiac sarcoid: a chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient, Echocardiography, 31, E138, 10.1111/echo.12536 · DOI
  45. Mehta, 2008, Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing, Chest, 133, 1426, 10.1378/chest.07-2784 · DOI
  46. Joyce, 2015, Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis, Eur J Heart Fail, 17, 51, 10.1002/ejhf.205 · DOI
  47. Blankstein, 2016, Evaluation of known or suspected cardiac sarcoidosis, Circ Cardiovasc Imaging, 9, 10.1161/CIRCIMAGING.113.000867 · DOI
  48. 2017, Eur Heart J Cardiovasc Imaging, 18, 1073, 10.1093/ehjci/jex146 · DOI
  49. Shimada, 2001, Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging, Am J Med, 110, 520, 10.1016/S0002-9343(01)00677-5 · DOI
  50. Smedema, 2005, Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis, J Am Coll Cardiol, 45, 1683, 10.1016/j.jacc.2005.01.047 · DOI
  51. Kouranos, 2017, Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis, JACC Cardiovasc Imaging, 10, 1437, 10.1016/j.jcmg.2016.11.019 · DOI
  52. Greulich, 2013, CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis, JACC Cardiovasc Imaging, 6, 501, 10.1016/j.jcmg.2012.10.021 · DOI
  53. Chareonthaitawee, 2017, Joint SNMMI-ASNC expert consensus document on the role of F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring, J Nucl Cardiol, 24, 1741, 10.1007/s12350-017-0978-9 · DOI
  54. Youssef, 2012, The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience, J Nucl Med, 53, 241, 10.2967/jnumed.111.090662 · DOI
  55. Blankstein, 2014, Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis, J Am Coll Cardiol, 63, 329, 10.1016/j.jacc.2013.09.022 · DOI
  56. Ahmadian, 2014, Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis, J Nucl Cardiol, 21, 925, 10.1007/s12350-014-9901-9 · DOI
  57. Vita, 2018, Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis, Circ Cardiovasc Imaging, 11, 10.1161/CIRCIMAGING.117.007030 · DOI
  58. Uemura, 1999, Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies, Am Heart J, 138, 299, 10.1016/S0002-8703(99)70115-8 · DOI
  59. Liang, 2014, Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis, JACC Heart Fail, 2, 466, 10.1016/j.jchf.2014.03.015 · DOI
  60. Ardehali, 2005, A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy, Am Heart J, 150, 459, 10.1016/j.ahj.2004.10.006 · DOI
  61. Murtagh, 2016, Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance, Circ Cardiovasc Imaging, 9, 10.1161/CIRCIMAGING.115.003738 · DOI
  62. Juneau, 2018, How common is isolated cardiac sarcoidosis? Extra-cardiac and cardiac findings on clinical examination and whole-body (18)F-fluorodeoxyglucose positron emission tomography, Int J Cardiol, 253, 189, 10.1016/j.ijcard.2017.09.204 · DOI
  63. Okada, 2018, Isolated cardiac sarcoidosis: a focused review of an under-recognized entity, J Nucl Cardiol, 25, 1136, 10.1007/s12350-016-0658-1 · DOI
  64. Rosenbaum, 2021, Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease, Int J Cardiol, 10.1016/j.ijcard.2021.04.022 · DOI
  65. Smith, 2020, Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy, Circulation, 141, 1872, 10.1161/CIRCULATIONAHA.119.044934 · DOI · Paper page
  66. Kransdorf, 2016, Pathology of chronic Chagas cardiomyopathy in the United States: a detailed review of 13 cardiectomy cases, Am J Clin Pathol, 146, 191, 10.1093/ajcp/aqw098 · DOI
  67. Vasaiwala, 2009, Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia, J Cardiovasc Electrophysiol, 20, 473, 10.1111/j.1540-8167.2008.01351.x · DOI
  68. Philips, 2014, Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear, Circ Arrhythm Electrophysiol, 7, 230, 10.1161/CIRCEP.113.000932 · DOI
  69. Asimaki, 2011, Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy, Circ Arrhythm Electrophysiol, 4, 743, 10.1161/CIRCEP.111.964890 · DOI · Paper page
  70. Haley, 2017, Cardiac sarcoidosis presenting as hypertrophic cardiomyopathy, Eur Heart J, 38, 2377, 10.1093/eurheartj/ehx132 · DOI
  71. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 128, 1810, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  72. Houston, 2014, Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach, Clin Med Insights Cardiol, 8, 31
  73. Pelliccia, 2019, Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC), Eur Heart J, 40, 19, 10.1093/eurheartj/ehy730 · DOI
  74. Bozkurt, 2021, Cardiac rehabilitation for patients with heart failure: JACC expert panel, J Am Coll Cardiol, 77, 1454, 10.1016/j.jacc.2021.01.030 · DOI
  75. Banba, 2007, Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis, Heart Rhythm, 4, 1292, 10.1016/j.hrthm.2007.06.006 · DOI
  76. Okada, 2018, Ventricular arrhythmias in cardiac sarcoidosis, Circulation, 138, 1253, 10.1161/CIRCULATIONAHA.118.034687 · DOI
  77. Yatsynovich, 2018, Updates on the role of imaging in cardiac sarcoidosis, Curr Treat Options Cardiovasc Med, 20, 74, 10.1007/s11936-018-0670-7 · DOI
  78. Yalagudri, 2017, Tailored approach for management of ventricular tachycardia in cardiac sarcoidosis, J Cardiovasc Electrophysiol, 28, 893, 10.1111/jce.13228 · DOI
  79. Papageorgiou, 2018, Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review, Europace, 20, 682, 10.1093/europace/eux077 · DOI
  80. Okada, 2019, Cardiac sympathectomy for refractory ventricular arrhythmias in cardiac sarcoidosis, Heart Rhythm, 16, 1408, 10.1016/j.hrthm.2019.02.025 · DOI
  81. Rosenthal, 2020, Risk of adverse cardiovascular events in cardiac sarcoidosis independent of left ventricular function, Am J Cardiol, 127, 142, 10.1016/j.amjcard.2020.04.025 · DOI
  82. Coleman, 2017, Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis, JACC Cardiovasc Imaging, 10, 411, 10.1016/j.jcmg.2016.05.009 · DOI
  83. Gowani, 2020, Utility of cardiac magnetic resonance imaging versus cardiac positron emission tomography for risk stratification for ventricular arrhythmias in patients with cardiac sarcoidosis, Am J Cardiol, 134, 123, 10.1016/j.amjcard.2020.08.007 · DOI
  84. Aizer, 2005, Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis, Am J Cardiol, 96, 276, 10.1016/j.amjcard.2005.03.059 · DOI
  85. Nordenswan, 2018, Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block, Circ Arrhythm Electrophysiol, 11, 10.1161/CIRCEP.117.006145 · DOI
  86. Patel, 2019, Effect of cardiac resynchronization therapy on left ventricular remodeling in patients with cardiac sarcoidosis, Am J Cardiol, 123, 329, 10.1016/j.amjcard.2018.09.044 · DOI
  87. Cain, 2014, Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias, Am J Cardiol, 113, 1556, 10.1016/j.amjcard.2014.01.434 · DOI
  88. Habibi, 2021, Multimodality imaging of atrial remodeling and risk of atrial fibrillation in patients with cardiac sarcoidosis, JACC Cardiovasc Imaging, 14, 700, 10.1016/j.jcmg.2020.08.037 · DOI
  89. Yazaki, 2001, Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone, Am J Cardiol, 88, 1006, 10.1016/S0002-9149(01)01978-6 · DOI
  90. Okada, 2020, Effect of corticosteroid dose and duration on 18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis, JACC Cardiovasc Imaging, 13, 1280, 10.1016/j.jcmg.2019.12.013 · DOI
  91. Sadek, 2013, Corticosteroid therapy for cardiac sarcoidosis: a systematic review, Can J Cardiol, 29, 1034
  92. Takaya, 2015, Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis, Am J Cardiol, 115, 505, 10.1016/j.amjcard.2014.11.028 · DOI
  93. Nagai, 2016, Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis, Am J Cardiol, 117, 966, 10.1016/j.amjcard.2015.12.033 · DOI
  94. Osborne, 2014, Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis, J Nucl Cardiol, 21, 166, 10.1007/s12350-013-9828-6 · DOI
  95. Segawa, 2016, Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis, Circ Arrhythm Electrophysiol, 9, 10.1161/CIRCEP.115.003353 · DOI
  96. Fillâtre, 2014, Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients, Am J Med, 12
  97. Rosenthal, 2019, Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis, J Am Heart Assoc, 8, 10.1161/JAHA.118.010952 · DOI
  98. Birnie, 2020, Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT), Am Heart J, 220, 246, 10.1016/j.ahj.2019.10.003 · DOI
  99. Allison, 2005, Mechanisms of action of mycophenolate mofetil, Lupus, 14, s2, 10.1177/096120330501400102 · DOI · Paper page
  100. Hamzeh, 2014, Efficacy of mycophenolate mofetil in sarcoidosis, Respir Med, 108, 1663, 10.1016/j.rmed.2014.09.013 · DOI
  101. Brill, 2013, Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study, Respiration, 86, 376, 10.1159/000345596 · DOI
  102. Griffin, 2021, Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid Sparing Agent, J Card Fail, 10.1016/j.cardfail.2021.06.010 · DOI
  103. Chung, 2003, Circulation, 107, 3133, 10.1161/01.CIR.0000077913.60364.D2 · DOI · Paper page
  104. Harper, 2019, Infliximab for refractory cardiac sarcoidosis, Am J Cardiol, 124, 1630, 10.1016/j.amjcard.2019.07.067 · DOI
  105. Gilotra, 2020, Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience, J Card Fail, 27, 83, 10.1016/j.cardfail.2020.08.013 · DOI
  106. Baker, 2020, TNF-alpha inhibition for the treatment of cardiac sarcoidosis, Semin Arthritis Rheum, 50, 546, 10.1016/j.semarthrit.2019.11.004 · DOI
  107. Bongartz, 2006, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, JAMA, 295, 2275, 10.1001/jama.295.19.2275 · DOI
  108. Elwazir, 2021, Rituximab for the Treatment of Refractory Cardiac Sarcoidosis-A Single Center Experience, J Card Fail
  109. Gilotra, 2020, Management of cardiac sarcoidosis in 2020, Arrhythm Electrophysiol Rev, 9, 182, 10.15420/aer.2020.09 · DOI
  110. Mehra, 2016, The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update, J Heart Lung Transplant, 35, 1, 10.1016/j.healun.2015.10.023 · DOI
  111. Crawford, 2018, A contemporary analysis of heart transplantation and bridge-to-transplant mechanical circulatory support outcomes in cardiac sarcoidosis, J Card Fail, 24, 384, 10.1016/j.cardfail.2018.02.009 · DOI
  112. Zaidi, 2007, Outcome of heart transplantation in patients with sarcoid cardiomyopathy, J Heart Lung Transplant, 26, 714, 10.1016/j.healun.2007.05.006 · DOI
  113. Patel, 2017, Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis, J Card Fail, 23, 859, 10.1016/j.cardfail.2017.09.011 · DOI
  114. Akashi, 2012, Outcome of patients with cardiac sarcoidosis undergoing cardiac transplantation–single-center retrospective analysis, J Cardiol, 60, 407, 10.1016/j.jjcc.2012.07.013 · DOI
  115. Sperry, 2016, Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure, J Heart Lung Transplant, 35, 392, 10.1016/j.healun.2015.12.005 · DOI
  116. Segura, 2014, Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device, Cardiovasc Pathol, 23, 17, 10.1016/j.carpath.2013.06.005 · DOI
  117. Schmidt, 2021, Natural history of patients diagnosed with cardiac sarcoidosis at left ventricular assist device implantation or cardiac transplantation, ASAIO J, 67, 583, 10.1097/MAT.0000000000001262 · DOI
  118. Griffin, 2020, Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system, Clin Transplant, 34, e14109, 10.1111/ctr.14109 · DOI
  119. Perkel, 2013, Heart transplantation for end-stage heart failure due to cardiac sarcoidosis, Transplant Proc, 45, 2384, 10.1016/j.transproceed.2013.02.116 · DOI
  120. Wirnsberger, 1998, Evaluation of quality of life in sarcoidosis patients, Respir Med, 92, 750, 10.1016/S0954-6111(98)90007-5 · DOI
  121. Chang, 2001, Depression in sarcoidosis, Am J Respir Crit Care Med, 163, 329, 10.1164/ajrccm.163.2.2004177 · DOI
  122. Sharp, 2019, Psychological burden associated with worse clinical outcomes in sarcoidosis, BMJ Open Respir Res, 6
  123. Arkema, 2018, Work ability before and after sarcoidosis diagnosis in Sweden, Respir Med, 144, S7, 10.1016/j.rmed.2018.09.016 · DOI
  124. Harper, 2020, Income and other contributors to poor outcomes in U.S. patients with sarcoidosis, Am J Respir Crit Care Med, 201, 955, 10.1164/rccm.201906-1250OC · DOI
  125. Rabin, 2004, Sarcoidosis: social predictors of severity at presentation, Eur Respir J, 24, 601, 10.1183/09031936.04.00070503 · DOI
  126. Kajdasz, 1999, Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators, Am J Epidemiol, 150, 271, 10.1093/oxfordjournals.aje.a009998 · DOI
  127. Israel, 1986, Factors affecting outcome of sarcoidosis. Influence of race, extrathoracic involvement, and initial radiologic lung lesions, Ann N Y Acad Sci, 465, 609, 10.1111/j.1749-6632.1986.tb18537.x · DOI
  128. Gerke, 2012, Increased hospitalizations among sarcoidosis patients from 1998 to 2008: a population-based cohort study, BMC Pulm Med, 12, 19, 10.1186/1471-2466-12-19 · DOI
  129. Michielsen, 2007, Relationship between symptoms and quality of life in a sarcoidosis population, Respiration, 74, 401, 10.1159/000092670 · DOI

Cited by

Sorted by citations

Metadata

Authors
Gilotra, N. A., GRIFFIN, J. M., PAVLOVIC, N., HOUSTON, B. A., CHASLER, J., GOETZ, C., CHRISPIN, J., SHARP, M., KASPER, E. K., CHEN, E. S., BLANKSTEIN, R., COOPER, L. T., JOYCE, E., & SHEIKH, F. H.
Affiliations
  • Johns Hopkins University (US)
  • Columbia University Irving Medical Center (US)
  • Medical University of South Carolina (US)
  • Georgetown University (US)
  • Brigham and Women's Hospital (US)
  • Mayo Clinic (US)
  • University College Dublin (IE)
Corresponding author
Gilotra, NISHA A.
ORCID
Venue
Journal of Cardiac Failure
Publisher
Elsevier BV
Published
2022-01
Volume
28
Issue
1
Pages
113-132
ISSN
1071-9164 (ISSN-L)
DOI
10.1016/j.cardfail.2021.06.016
PMC
PMC8748280
OpenAlex
W3180276185
Cited by
94
References
1
Citations by year
2026: 16 · 2025: 25 · 2024: 22 · 2023: 18 · 2022: 11
FWCI
1.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Cardiac Failure (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (K23HL148527)
  • National Institute of Nursing Research (T32NR012704)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoidosis and Beryllium Toxicity Research
  • Health Sciences › Medicine › Hematology › Histiocytic Disorders and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords
cardiac sarcoidosis, granulomatous myocarditis, cardiac conduction disorders, ventricular arrhythmias, heart failure, arrhythmogenic cardiomyopathy, cardiac imaging, immunosuppressive therapy, ventricular assist devices, heart transplantation
MeSH terms
Heart Failure, Humans, Cardiomyopathies, Myocarditis, Sarcoidosis, Heart Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review